1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Shuttle Pharma Receives US Patent for Selective Histone Deacetylase Inhibitors

10 Sep 2024
Admin
News Article

Shuttle Pharma Receives US Patent for Selective Histone Deacetylase Inhibitors

Shuttle Pharma receives US patent for selective histone deacetylase inhibitors for the treatment of human disease

Overview

Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company, announced the issuance of US Patent No. 12,077,515, titled “Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease.” This patent was officially issued on September 3, 2024, further strengthening Shuttle Pharma’s intellectual property portfolio and supporting its ongoing efforts to develop novel therapeutics targeting histone deacetylase (HDAC) enzymes.

Selective HDAC Inhibitors

The newly issued patent covers a series of selective HDAC inhibitors designed to modulate the expression of genes involved in cancer progression, immune responses, and other critical biological pathways.
These inhibitors are being developed as potential treatments for a range of human diseases, including cancer.

Primary Purpose: Shuttle Pharma

Shuttle Pharma’s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy.
Shuttle Pharma has deployed its proprietary technology to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
Shuttle Pharma’s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including autoimmune, inflammatory, metabolic, neurological and infectious diseases.

Words from the CEO: Shuttle Pharmaceuticals

“We are excited to receive this patent, which reflects our commitment to pioneering therapies that address significant unmet medical needs,” said Anatoly Dritschilo, MD, CEO of Shuttle Pharmaceuticals.
“These drug candidates were invented by Shuttle Pharma’s scientists based on our strategy to selectively inhibit HDAC6 for regulation of the innate immune response to irradiated cancer cells. This achievement underscores Shuttle Pharmaceuticals’ role at the forefront of innovative drug development and positions us for further advances in our clinical pipeline.”

About Shuttle Pharma

Shuttle Pharma now holds more than 20 composition of matter HDAC inhibitor patents in the US, Canada and Europe.
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT).